Document Detail


Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism.
MedLine Citation:
PMID:  19370896     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To document the rate of clinically significant venous thromboembolism (VTE) in patients with clear cell carcinoma of the endometrium (CCC-E). STUDY DESIGN: Institutional review board permission was obtained to identify all cases of CCC-E between 1994 and 2004. Controls with high grade endometrial cancers were matched for stage, age and date of diagnosis. RESULTS: Complete data were available for 29. Age ranged from 38 to 85 (mean, 64.6) years. Thirty-five percent of the patients had stage I tumors, 10% stage II, 27.5% stage III and 27.5% stage IV tumors. Fifty-eight matched controls were selected. Overall there were 18 VTE events: 10 (34.5%) in patients with CCC-E and 8 (13.8%) in the controls (OR = 3.68, p = 0.032). More VTE occurred in patients with stage III/IV disease (n = 16) than those with early stage (n = 2). VTE in patients with CCC-E occurred at presentation or with disease recurrence rather than in the postoperative period (8 vs. 1). Among patients with CCC-E, VTE had an adverse effect on survival, with a hazard ratio of 3.65 (95% CI, 3.14-4.16; p = 0.011). CONCLUSION: Patients with CCC-E have greater risk of VTE than patients with other high-risk endometrial cancers. Consideration should be given to extended prophylaxis in patients with CCC-E to prevent VTE.
Authors:
Lisa Lee; Leslie Garrett; Hang Lee; Esther Oliva; Neil Horowitz; Linda R Duska
Related Documents :
16854456 - Cd105 expression is an independent predictor of survival in patients with endometrial c...
7337406 - Results of treatment of endometrial cancer in tampere university central hospital 1962-...
12821356 - The effect of body mass index on clinical/pathologic features, surgical morbidity, and ...
23943256 - The 3.5-year survival rates of primary molars treated according to three treatment prot...
21216486 - Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer...
16854456 - Cd105 expression is an independent predictor of survival in patients with endometrial c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of reproductive medicine     Volume:  54     ISSN:  0024-7758     ISO Abbreviation:  J Reprod Med     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-04-17     Completed Date:  2009-05-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0173343     Medline TA:  J Reprod Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  133-8     Citation Subset:  IM    
Affiliation:
Division of Gynecologic Oncology, Biostatistics Center, Massachusetts General Hospital, Boston, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma, Clear Cell / epidemiology*,  mortality,  pathology
Adult
Aged
Aged, 80 and over
Case-Control Studies
Comorbidity
Confounding Factors (Epidemiology)
Endometrial Neoplasms / epidemiology*,  mortality,  pathology
Female
Fibrinolytic Agents / therapeutic use*
Humans
Middle Aged
Neoplasm Staging
Primary Prevention
Venous Thromboembolism / epidemiology*,  mortality,  pathology
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hysterosalpingography with selective salpingography.
Next Document:  Effects of wound closure on wound healing in gynecologic surgery: a systematic literature review.